Pharmacokinetic enhancer, penicillin antibiotics:
Children ≥2 years and Adolescents: Note: Dosing for specific indications may vary; use has also been described with some cephalosporins (Ref).
Patient weight ≤50 kg:
Weight-directed dosing:
Initial: Oral: 25 mg/kg/dose as a single dose.
Maintenance: Oral: 10 mg/kg/dose 4 times daily; maximum dose: 500 mg/dose.
BSA-directed dosing:
Initial: Oral: 700 mg/m2/dose as a single dose.
Maintenance: Oral: 300 mg/m2/dose 4 times daily; maximum dose: 500 mg/dose.
Patient weight >50 kg: Oral: 500 mg 4 times daily.
Sexually transmitted infections, as a beta-lactam pharmacokinetic enhancer (adjunctive agent):
Gonococcal infection, uncomplicated infection of cervix, urethra, or rectum: Adolescents: Oral: 1,000 mg as a single dose concomitantly with a single dose of cefoxitin (Ref).
Pelvic inflammatory disease: Children weighing ≥45 kg and Adolescents: Oral: 1,000 mg as a single dose, concomitantly with a single dose of cefoxitin (as part of an appropriate combination regimen) (Ref).
Neurosyphilis (alternative regimen): Note: IV therapy is preferred. Use only in patients in whom compliance can be ensured (Ref).
Adolescents: Oral: 500 mg 4 times daily with procaine penicillin for 10 to 14 days (Ref).
Cidofovir nephrotoxicity, prevention: Limited data available; various regimens have been reported:
Infants, Children, and Adolescents: Note: The manufacturer's labeling considers use in patients <2 years of age to be contraindicated; however, clinical studies have included younger ages (including infants) for this indication. Use in combination with IV fluid hydration.
Weight-directed dosing: Oral: 25 to 40 mg/kg/dose (maximum dose: 2,000 mg/dose) administered 3 hours before cidofovir infusion and 10 to 20 mg/kg/dose (maximum dose: 1,000 mg/dose) at 2 to 3 hours and 8 to 9 hours after cidofovir infusion (Ref).
BSA-directed dosing: Oral: 1,000 or 1,250 mg/m2/dose (maximum dose: 2,000 mg/dose) administered 3 hours prior to cidofovir, followed by 500 to 1,250 mg/m2/dose (maximum dose: 1,000 mg/dose) 1 to 3 hours and 8 hours after completion (Ref).
Children ≥2 years and Adolescents: CrCl <30 mL/minute: Avoid use (reduced efficacy with renal impairment).
There are no dosage adjustments provided in the manufacturer's labeling.
(For additional information see "Probenecid: Drug information")
Cidofovir nephrotoxicity, prevention (off-label use): Oral: 2 g as a single dose administered 3 hours before cidofovir infusion, followed by 1 g at 2 hours and 8 hours after cidofovir infusion (Ref).
Hyperuricemia, gout prevention (alternative agent): Oral: 250 mg twice daily for 1 week, followed by 500 mg twice daily; may increase dose by 500 mg every 4 weeks as tolerated if symptoms are not controlled; usual maintenance dose: ≤2 g/day in divided doses.
Sexually transmitted infections, as a beta-lactam pharmacokinetic enhancer (adjunctive agent):
Gonococcal infection, uncomplicated: Oral: 1 g as a single dose in combination with single-dose IM cefoxitin (Ref).
Neurosyphilis, including ocular and otosyphilis:
Note: Reserve for patients unable to receive IV therapy (Ref).
Oral: 500 mg 4 times daily in combination with IM procaine penicillin for 10 to 14 days (Ref).
Pelvic inflammatory disease, mild to moderate: Oral: 1 g as a single dose in combination with IM cefoxitin as a single dose plus doxycycline and metronidazole (Ref).
The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Altered kidney function
eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary (Ref).
eGFR <60 mL/minute/1.73 m2:
Cidofovir nephrotoxicity, prevention (off-label use):
Oral: No dosage adjustment of probenecid likely necessary (Ref). Note: The use and dose of cidofovir in patients with kidney dysfunction should be evaluated separately.
Hyperuricemia, gout prevention: Oral:
eGFR ≥30 to <60 mL/minute/1.73 m2: The use of alternative agents is recommended due to reduced efficacy of probenecid in patients with eGFR <60 mL/minute/1.73 m2 (Ref). If use of probenecid is deemed appropriate, no dosage adjustment likely necessary; however, use with caution and frequent monitoring for safety and efficacy. Limited data demonstrate urate-lowering capability of probenecid in patients with eGFR 30 to 60 mL/minute/1.73 m2 without increased risk of toxicity; however, robust evidence is lacking, and better alternatives are often available (Ref).
eGFR <30 mL/minute/1.73 m2: Use not recommended (Ref).
Sexually transmitted infections, as a pharmacokinetic enhancer to prolong beta-lactam serum levels: Oral:
Note: No dosage adjustment is necessary for single dose probenecid regimens (ie, used in combination with cefoxitin for gonococcal infection or pelvic inflammatory disease) (Ref).
eGFR <60 mL/minute/1.73 m2: Since probenecid may have limited efficacy in reducing the renal clearance of beta-lactam concentrations (ie, procaine penicillin) in patients with kidney impairment, the use of probenecid in combination with procaine penicillin for the treatment of neurosyphilis should be avoided (Ref).
Hemodialysis, intermittent (thrice weekly): Oral: Avoid use (Ref).
Peritoneal dialysis: Oral: Avoid use (Ref).
CRRT: Oral: Avoid use (Ref).
PIRRT (eg, sustained, low-efficiency diafiltration): Oral: Avoid use (Ref).
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Frequency not defined:
Cardiovascular: Flushing
Dermatologic: Alopecia, dermatitis, pruritus, urticaria
Gastrointestinal: Anorexia, gingival pain, nausea, vomiting
Genitourinary: Urinary frequency
Hematologic & oncologic: Anemia, aplastic anemia, hemolytic anemia, leukopenia
Hepatic: Hepatic necrosis
Nervous system: Dizziness, headache, pain (costovertebral)
Renal: Nephrolithiasis, nephrotic syndrome, renal colic
Miscellaneous: Fever
Postmarketing: Hypersensitivity: Anaphylaxis, severe hypersensitivity reaction
Hypersensitivity to probenecid or any component of the formulation; blood dyscrasias; uric acid kidney stones; children <2 years of age; initiation during an acute gout attack.
Concerns related to adverse effects:
• Hypersensitivity reaction: Has been associated with rare, severe hypersensitivity reactions, including anaphylaxis. Discontinue therapy if reaction occurs.
• Gout: May cause exacerbation of acute gouty attack.
Disease-related concerns:
• G6PD deficiency: Use caution in patients with G6PD deficiency; may increase risk for hemolytic anemia.
• Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.
• Kidney impairment: May not be effective in patients with kidney impairment; use with caution (ACR [FitzGerald 2020]; manufacturer’s labeling).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet, Oral:
Generic: 500 mg
Yes
Tablets (Probenecid Oral)
500 mg (per each): $0.98 - $3.73
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Oral: Administer with food to minimize GI effects (Ref).
Oral: Administer with food to minimize GI effects. Maintain adequate fluid intake.
Store at 20°C to 25°C (68°F to 77°F). Protect from light.
Adjuvant to therapy with penicillins to elevate and prolong serum concentrations (FDA approved in ages ≥2 years and adults); treatment of hyperuricemia associated with gout and gouty arthritis (FDA approved in adults); has also been used with cephalosporin therapy to prolong serum concentrations and to prevent nephrotoxicity associated with cidofovir therapy.
Probenecid may be confused with Procanbid
Inhibits MRP2, OAT1/3, UGT1A4, UGT1A6;
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
Acetaminophen: Probenecid may increase serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite. Management: Consider limiting acetaminophen use in combination with probenecid. Probenecid may reduce clearance of acetaminophen to one of its non-toxic metabolities, increasing the risk for acetaminophen toxicity, even a lower doses. Risk D: Consider Therapy Modification
Anagliptin: Probenecid may increase serum concentration of Anagliptin. Risk C: Monitor
Avibactam: Probenecid may increase serum concentration of Avibactam. Risk X: Avoid
Baricitinib: Probenecid may increase serum concentration of Baricitinib. Management: When baricitinib is combined with probenecid, reduce baricitinib 4 mg daily to 2 mg daily or reduce baricitinib 2 mg daily to 1 mg daily. Don't use probenecid if recommended baricitinib dose is only 1 mg daily. Risk D: Consider Therapy Modification
Betalactamase Inhibitors: Probenecid may increase serum concentration of Betalactamase Inhibitors. Management: Coadministration of probenecid with amoxicillin/clavulanate is not recommended per official package labeling. Risk D: Consider Therapy Modification
Cabozantinib: MRP2 Inhibitors may increase serum concentration of Cabozantinib. Risk C: Monitor
Cefotaxime: Probenecid may increase serum concentration of Cefotaxime. Management: Avoid cefotaxime doses greater than 6 grams per day with concurrent probenecid. Any patients receiving this combination should be monitored for evidence of cefotaxime toxicity. Risk D: Consider Therapy Modification
Cephalosporins: Probenecid may increase serum concentration of Cephalosporins. Risk C: Monitor
Certoparin: Probenecid may increase anticoagulant effects of Certoparin. Risk C: Monitor
Clofarabine: OAT1/3 Inhibitors may increase serum concentration of Clofarabine. Risk C: Monitor
Deferiprone: UGT1A6 Inhibitors may increase serum concentration of Deferiprone. Risk X: Avoid
Dexketoprofen: Probenecid may increase serum concentration of Dexketoprofen. Risk C: Monitor
Dichlorphenamide: OAT1/3 Inhibitors may increase serum concentration of Dichlorphenamide. Risk C: Monitor
Doripenem: Probenecid may increase serum concentration of Doripenem. Risk X: Avoid
Dyphylline: Probenecid may increase serum concentration of Dyphylline. Risk C: Monitor
Ertapenem: Probenecid may increase serum concentration of Ertapenem. Risk X: Avoid
Ganciclovir-Valganciclovir: Probenecid may increase serum concentration of Ganciclovir-Valganciclovir. Risk C: Monitor
Gemifloxacin: Probenecid may increase serum concentration of Gemifloxacin. Risk C: Monitor
Imipenem: Probenecid may increase serum concentration of Imipenem. Risk C: Monitor
Ketoprofen: Probenecid may increase serum concentration of Ketoprofen. Risk X: Avoid
Ketorolac (Nasal): Probenecid may increase serum concentration of Ketorolac (Nasal). Risk X: Avoid
Ketorolac (Systemic): Probenecid may increase serum concentration of Ketorolac (Systemic). Risk X: Avoid
Loop Diuretics: Probenecid may decrease diuretic effects of Loop Diuretics. Probenecid may increase serum concentration of Loop Diuretics. Risk C: Monitor
LORazepam: Probenecid may increase serum concentration of LORazepam. Management: Reduce lorazepam dose 50% during coadministration with probenecid. Monitor for increased and prolonged lorazepam effects, particularly CNS depressant effects. Patients using lorazepam ER capsules should be switched to lorazepam tablets. Risk D: Consider Therapy Modification
Meropenem: Probenecid may increase serum concentration of Meropenem. Risk X: Avoid
Methotrexate: Probenecid may increase serum concentration of Methotrexate. Management: If possible, the concomitant use of methotrexate and probenecid should be avoided. If used concomitantly, monitor closely for increased methotrexate serum concentrations and toxicities. Methotrexate dose reductions may be needed. Risk D: Consider Therapy Modification
Mycophenolate: Probenecid may increase serum concentration of Mycophenolate. Risk C: Monitor
Nitrofurantoin: Probenecid may decrease therapeutic effects of Nitrofurantoin. Probenecid may increase serum concentration of Nitrofurantoin. Risk C: Monitor
Nonsteroidal Anti-Inflammatory Agents: Probenecid may increase serum concentration of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor
Oseltamivir: Probenecid may increase active metabolite exposure of Oseltamivir. Risk C: Monitor
Pegloticase: Probenecid may increase adverse/toxic effects of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions. Risk X: Avoid
Penicillins: Probenecid may increase serum concentration of Penicillins. Risk C: Monitor
Pexidartinib: UGT1A4 Inhibitors may increase serum concentration of Pexidartinib. Management: If combined use cannot be avoided, pexidartinib dose should be reduced as follows: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily; reduce pexidartinib 250 mg daily to 125 mg once daily. Risk D: Consider Therapy Modification
Phenprocoumon: Probenecid may decrease serum concentration of Phenprocoumon. Risk C: Monitor
PRALAtrexate: Probenecid may increase serum concentration of PRALAtrexate. Management: Avoid coadministration of pralatrexate with probenecid. If coadministration cannot be avoided, closely monitor for increased pralatrexate serum concentrations or possible toxicity with concomitant use of probenecid. Risk D: Consider Therapy Modification
Propacetamol: Probenecid may increase active metabolite exposure of Propacetamol. Specifically, accetaminophen exposure may be increased. Probenecid may also limit the formation of at least one major non-toxic acetaminophen metabolite, possibly increasing the formation of the toxic NAPQI metabolite. Management: Consider limiting the use of propacetamide in patients who are also taking probenecid. Patients may be at an increased risk for toxicity, even if reduced propacetamide doses are used. Risk D: Consider Therapy Modification
Quinolones: Probenecid may increase serum concentration of Quinolones. Probenecid may decrease excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Risk C: Monitor
RifAMPin: Probenecid may increase serum concentration of RifAMPin. Risk C: Monitor
Roxadustat: Probenecid may increase serum concentration of Roxadustat. Risk C: Monitor
Salicylates: May decrease therapeutic effects of Probenecid. Salicylates may increase serum concentration of Probenecid. Probenecid may increase serum concentration of Salicylates. Risk X: Avoid
Seladelpar: OAT1/3 Inhibitors may increase serum concentration of Seladelpar. Risk X: Avoid
Sodium Benzoate: Probenecid may decrease therapeutic effects of Sodium Benzoate. Risk C: Monitor
Sulbactam: Probenecid may increase serum concentration of Sulbactam. Management: Recommendations for management of this interaction vary by specific sulbactam-containing product. Coadministration of probenecid with sulbactam/durlobactam is not recommended, but no specific actions are recommended for ampicillin/sulbactam. Risk D: Consider Therapy Modification
Sulfonylureas: Probenecid may increase serum concentration of Sulfonylureas. Risk C: Monitor
Thiopental: Probenecid may increase adverse/toxic effects of Thiopental. Specifically, anesthetic potency and duration may be enhanced. Risk C: Monitor
Urea Cycle Disorder Agents: Probenecid may increase active metabolite exposure of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased. Risk C: Monitor
Vadadustat: OAT1/3 Inhibitors may increase serum concentration of Vadadustat. Risk C: Monitor
Zidovudine: Probenecid may increase serum concentration of Zidovudine. Risk C: Monitor
Drug may cause GI upset; take with food if GI upset. Drink plenty of fluids.
Probenecid crosses the placenta.
Outcome data following maternal use of probenecid during pregnancy are limited (Gutman 2012).
Kidney function, CBC; monitor for GI upset.
Competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby promoting its excretion and reducing serum uric acid levels; increases plasma levels of weak organic acids (penicillins, cephalosporins, or other beta-lactam antibiotics) by competitively inhibiting their renal tubular secretion
Onset of action: Effect on penicillin levels: 2 hours; Uric acid renal clearance: 30 minutes
Absorption: Rapid and complete
Protein binding: 85% to 95%
Metabolism: Hepatic
Half-life elimination (dose dependent): Normal renal function: 6 to 12 hours
Time to peak, serum: 2 to 4 hours
Excretion: Urine